Internal Medicine, Hematology & Oncology · Royal Oak, MI
NPI
1891701082
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
3577 W 13 Mile Rd Ste 103
Royal Oak, MI, 48073
Phone (248) 288-4500
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
131,059 services
Medicare patients, 2024
672
Average age 75
Drug cost, 2024
$2.9M
1,090 prescriptions
Company payments, 2025
$1,989
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohammed Ibrahim was code J1439 (injection, ferric carboxymaltose, 1 mg), 18,750 times for 23 patients. In total Mohammed Ibrahim billed 131,059 services in 148 codes, and Medicare paid $2.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-04-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 18,750 | 23 | $0.87 | $16K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 11,730 | 18 | $0.29 | $3,457 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 10,400 | 18 | $44.83 | $466K |
| J0897 Injection, denosumab, 1 mg | Office | 6,060 | 38 | $20.84 | $126K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 5,808 | 14 | $20.28 | $118K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,600 | 19 | $0.11 | $402 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,820 | 27 | $6.48 | $18K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2,600 | 12 | $2.21 | $5,746 |
| 36415 Venipuncture Blood Collection | Office | 1,372 | 498 | $8.64 | $12K |
| 85025 Blood Count | Office | 1,299 | 469 | $7.59 | $9,864 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,140 | 45 | $0.68 | $772 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 754 | 46 | $0.09 | $68.13 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 568 | 224 | $13.01 | $7,387 |
| 99213 Office E&M - Established | Office | 455 | 235 | $70.01 | $32K |
| 99215 Office E&M - Established | Office | 368 | 132 | $137.61 | $51K |
By year: 2022 $1.7M for 154,784 services; 2023 $1.9M for 135,992 services; 2024 $2.2M for 131,059 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,372 | 498 | $8.64 | $12K |
| 85025 Blood Count | 1,299 | 469 | $7.59 | $9,864 |
| 84100 Clinical Chemistry | 267 | 126 | $4.65 | $1,242 |
| 84550 Clinical Chemistry | 266 | 126 | $4.43 | $1,178 |
| 83615 Clinical Chemistry | 265 | 125 | $5.92 | $1,569 |
| 80048 Clinical Chemistry | 244 | 121 | $8.29 | $2,023 |
| 83735 Clinical Chemistry | 231 | 113 | $6.57 | $1,518 |
| 80076 Clinical Chemistry | 206 | 108 | $8.01 | $1,650 |
| 80053 Clinical Chemistry | 32 | 27 | $10.35 | $331 |
Medicare prescription drug claims, 2024
In 2024, the drug Mohammed Ibrahim prescribed most often to Medicare patients was Eliquis (Apixaban), with 97 prescriptions and refills. In total Mohammed Ibrahim wrote 1,090 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 97 | 218 | 30 | $121K |
| Hydroxyurea Generic | 65 | 149 | 19 | $3,070 |
| Anastrozole Generic | 64 | 183 | 22 | $3,664 |
| Lenalidomide Generic | 45 | 45 | Under 11 | $531K |
| Prochlorperazine Maleate Generic | 42 | 43 | 33 | $1,506 |
| Prednisone Generic | 41 | 51 | 26 | $189 |
| Acyclovir Generic | 38 | 84 | 11 | $908 |
| Xarelto Rivaroxaban | 35 | 100 | Under 11 | $52K |
| Imbruvica Ibrutinib | 24 | 24 | Under 11 | $267K |
| Nubeqa Darolutamide | 24 | 24 | Under 11 | $320K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 23 | 23 | 11 | $501 |
| Omeprazole Generic | 21 | 40 | 12 | $203 |
| Potassium Chloride Generic | 20 | 20 | 14 | $46.56 |
| Venclexta Venetoclax | 19 | 19 | Under 11 | $179K |
| Levofloxacin Generic | 19 | 19 | 11 | $165 |
Brand drugs: 328 claims; generic drugs: 762 claims; opioid claims: 81.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohammed Ibrahim $1,989 ($1,989 in general payments such as food, travel and fees) from 22 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,112.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 22 | $1,112 |
| Abbvie Inc. ABBV | 8 | $205 |
| Genzyme Corporation SNY | 3 | $62.92 |
| Genentech USA, Inc. ROG.SW | 3 | $62.31 |
| Pfizer Inc. PFE | 3 | $60.64 |
| Merck Sharp & Dohme LLC MRK | 2 | $51.08 |
| Kyowa Kirin, Inc. 4151.T | 2 | $50.54 |
| Aveo Pharmaceuticals, Inc. | 3 | $48.71 |
| Array Biopharma Inc PFE | 3 | $45.27 |
| Janssen Biotech, Inc. JNJ | 2 | $41.19 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.